Abstract
Currently, a large number of studies have been published supplementing our knowledge of sarcopenia and its effect on the development of metabolic disorders, including the formation of NAFLD. This data allows a new look at the pharmacological and non-pharmacological approaches to the treatment of NAFLD, based on basic physiological processes, including the biological axis of the muscle — the liver. This provides a compelling rationale for studying skeletal muscle as the main therapeutic target for NAFLD and metabolic syndrome.